priors.science/reviews/obesity-pharmacotherapy

Obesity Pharmacotherapy

The current evidence on 41 claims, ordered from most established to most contested. Each score is the panel’s evidence certainty — how firmly the literature supports the claim as stated.

41claims tracked

121primary papers reviewed

9 Aug 2026latest evidence review

Weeklyre-scored against new papers

19 Established · 17 Likely · 5 Uncertain · 0 Doubtful | four-reviewer panel · PICO Framework

ClaimStandingEvidence certaintyCorpus

Semaglutide 2.4 mg weekly reduces the risk of major adverse cardiovascular events (MACE) by approximately 20% in adults with established cardiovascular disease and overweight or obesity.CVEstablished94%3

Orlistat modest weight lossOLDEstablished93%2

Older approved anti-obesity pharmacotherapies (phentermine-topiramate, naltrexone-bupropion, orlistat) produce substantially less weight loss and have not demonstrated cardiovascular outcome benefits in large RCTs.OLDEstablished93%2

Tirzepatide > sema 2.4 mg weightCOMPEstablished92%5

Sema and tirz > older pharmacotherapyCOMPEstablished92%2

Semaglutide resolves steatohepatitisMETAEstablished91%3

Naltrexone-bupropion ~5-6% weightOLDEstablished91%2

Weight regain after tirzepatide cessationREGAINEstablished91%2

Sema 2.4 mg ~15% weight lossSEMAEstablished91%22

Tirzepatide sleep apnea reductionTIRZEstablished91%1

Phentermine-topiramate ~8-10% weightOLDEstablished90%3

Continuous therapy required for maintenanceREGAINEstablished90%5

Tirzepatide 15 mg ~21% weight lossTIRZEstablished89%16

Sema 2.4 mg > liraglutide 3 mgCOMPEstablished88%1

Gallbladder disease risk elevatedSAFEEstablished88%2

Anti-obesity pharmacotherapy heart failureCVEstablished86%3

Nausea, vomiting, diarrhoea, and constipation are the most common adverse events with GLP-1 receptor agonists and tirzepatide for obesity, occurring in 30–60% of treated participants and driving the majority of treatment discontinuations.SAFEEstablished86%6

Sema 2.4 mg adolescent obesitySEMAEstablished85%11

Liraglutide 3 mg 5–8% weight lossSEMAEstablished85%12

Retatrutide >20% weight phase 2EMERGLikely84%1

Weight regain after sema cessationREGAINLikely84%3

Sema 2.4 mg sustained on-treatmentSEMALikely84%11

Tirzepatide T2D+obesity weightTIRZLikely83%7

Emerging agents > sema and tirz weightCOMPLikely82%3

Semaglutide 2.4 mg slows eGFR decline and reduces albuminuria in people with overweight or obesity and chronic kidney disease.METALikely82%3

Tirzepatide sustained 104 weeksTIRZLikely81%4

Tirzepatide significantly reduces liver fibrosis and resolves MASH in adults with MASH and obesity.METALikely80%4

Sema 2.4 mg >50% achieve ≥15%SEMALikely80%22

Tirzepatide ≥20% in one-thirdTIRZLikely79%14

Oral non-peptide GLP-1 receptor agonists (orforglipron) achieve clinically meaningful weight loss of at least 10% in phase 3 trials in adults with obesity.EMERGLikely78%1

Sema and tirz blood pressure reductionMETALikely78%2

GLP-1 receptor agonists improve menstrual cycle regularity and reduce androgen levels in women with polycystic ovary syndrome and obesity.METALikely78%2

No increased pancreatitis riskSAFELikely76%2

Sema 2.4 mg all-cause mortalityCVLikely70%2

Cagrilintide plus semaglutide (CagriSema) achieves significantly greater body weight reduction than semaglutide monotherapy in adults with obesity.EMERGLikely70%4

Lifestyle intervention prevents regainREGAINLikely70%4

Cardiovascular benefit independent of weight lossCVUncertain68%2

Bimagrumab preserves lean massEMERGUncertain64%2

Non-arteritic anterior ischaemic optic neuropathy visual risk signalSAFEUncertain64%5

Tirzepatide cardiovascular outcomes trialCVUncertain58%5

Lean mass loss during treatmentSAFEUncertain56%4

Track Obesity Pharmacotherapy.

These claims are re-scored against new papers every week. Track this topic for the full review, including each claim’s challenge and the papers behind it.

Track this topic →

Standing — what the evidence certainty means

Established≥ 85%Strong, consistent evidence. Unlikely to change.

Likely70–84%Well supported, with some gaps or indirect evidence.

Uncertain50–69%Mixed or limited evidence. Genuinely open.

Doubtful30–49%Little support; the weight of evidence leans against it.

Refuted< 30%The evidence contradicts it — confidently false as stated.